Evidence map›Paper›PMID 41761395›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2026

Differentiated service delivery for TB treatment.

H B Mulenga, B K Moore, C Lyembele, E Kalunkumya, T Sinkala, L Mwiinga, P Lungu, J B Harris, S Bosomprah, C Banda and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

H B MulengaCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
B K MooreDivision of Global HIV and TB, Global TB Branch, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
C LyembeleCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
E KalunkumyaCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
T SinkalaCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
L MwiingaDivision of Global HIV and TB, US Centers for Disease Control and Prevention, Lusaka, Zambia.
P LunguNational TB and Leprosy Program, Ministry of Health, Lusaka, Zambia.
J B HarrisDivision of Global HIV and TB, Global TB Branch, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
S BosomprahCentre for Infectious Disease Research in Zambia, Lusaka, Zambia;, Department of Biostatistics, School of Public Health, University of Ghana, Accra, Ghana.
C BandaSouthern Provincial Health Office, Choma, Zambia.
C NkwemuCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
M W MwanzaCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
T SavoryCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
C B MooreCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
A MubangaNational TB and Leprosy Program, Ministry of Health, Lusaka, Zambia.
K ChiyenuLivingstone University Teaching Hospital, Livingstone, Zambia.
N BweupeLivingstone University Teaching Hospital, Livingstone, Zambia.
M ChiyalaLivingstone University Teaching Hospital, Livingstone, Zambia.
D ZacharyDivision of Global HIV and TB, US Centers for Disease Control and Prevention, Lusaka, Zambia.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

<sec><title>BACKGROUND</title>Differentiated service delivery (DSD) includes service decentralisation, multi-month medication dispensing, and treatment support. We describe demographic and clinical characteristics, treatment support, and outcomes among clients treated under a TB treatment DSD model in five facilities in Lusaka and Livingstone, Zambia, from February 2022 to March 2023.</sec><sec><title>METHODS</title>Medicines were dispensed for 2 months in intensive and 4 months in the continuation phases of TB treatment. Treatment support was provided through text message, phone, and home visits to monitor symptoms, adherence, and adverse events. Association between demographic, clinical, and treatment support variables and likelihood of successful treatment was examined using Pearson's χ² or Fisher's exact tests.</sec><sec><title>RESULTS</title>Among 970 clients treated under DSD, most were HIV-negative (72%) and had pulmonary TB (94%). Only 6% of the clients ever-responded to text-based surveys, while 85% were reached by phone or home visit. Overall, 83% of the clients were successfully treated for TB. Significant differences in treatment success were observed by facility (74%-91%,

Indexed as

Antitubercular AgentsDelivery of Health CareTuberculosisTuberculosis, PulmonaryAdolescentAdultFemaleHouse CallsHumansMaleMiddle AgedText MessagingTreatment OutcomeYoung AdultAntitubercular Agents

Identifiers

PMID41761395
PMCPMC13343347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.